The effect of Memantine on cognition disorders induced by Electroconvulsive therapy (ECT)

Electroconvulsive therapy (ECT) is a treatment for severe depression and other mental health conditions, but it can temporarily affect memory and thinking. This study is testing whether a medication called memantine — which is used to treat Alzheimer's disease — can protect against these memory and thinking changes when taken during ECT treatment. Participants will be randomly assigned to receive either memantine or a placebo before and during ECT, and cognitive testing will be done before and after. You may be eligible if: - You are between 18 and 60 years old - You are scheduled to undergo electroconvulsive therapy (ECT) at a participating hospital - You are able to give informed consent You may NOT be eligible if: - You have kidney or liver failure - You have a cardiac conduction block (a type of heart rhythm problem) - You are taking medications with anticholinergic or NMDA-blocking effects - You are pregnant or breastfeeding Talk to your doctor about whether this trial might be right for you.